Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.

Vito Ricci, ML Peterson, JC Rotschafer, H Wexler, Laura Piddock

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Twelve laboratory mutants and 32 ciprofloxacin-resistant isolates of Bacteroides fragilis were examined for the mechanism(s) of fluoroquinolone resistance. Five mutants had mutations in gyrA. One mutant and two clinical isolates contained a mutation in gyrB. Eight mutants and five clinical isolates accumulated significantly less ciprofloxacin than did wild-type isolates; the mutants and clinical isolates were restored to wild-type characteristics when carbonyl cyanide m-chlorophenylhydrazone was used.
Original languageEnglish
Pages (from-to)1344-6
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume48
Issue number4
Publication statusPublished - 1 Apr 2004

Fingerprint

Dive into the research topics of 'Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants.'. Together they form a unique fingerprint.

Cite this